Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: Results from a randomized, double-blind, controlled clinical trial

• Published in: Ophthalmology (Rochester, Minn.) Vol. 108; no. 7; pp. 1179 - 1183
• Main Authors: Asaria, Riaz Hassan Yusuf, Kon, Chee Hing, Bunce, Catey, Charteris, David G, Wong, David, Khaw, Peng Tee, Aylward, George William
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 2001; Elsevier
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Biological and medical sciences; Double-Blind Method; Drug Therapy, Combination; Eye; Female; Fluorouracil - therapeutic use; Follow-Up Studies; Heparin, Low-Molecular-Weight - therapeutic use; Humans; Male; Medical sciences; Middle Aged; Ophthalmology; Pharmacology. Drug treatments; Prospective Studies; Retinal Detachment - surgery; Retinopathies; Risk Factors; Safety; Visual Acuity; Vitrectomy - adverse effects; Vitreoretinopathy, Proliferative - etiology; Vitreoretinopathy, Proliferative - prevention & control; Human; Retinal detachment; Drug combination; Chemoprophylaxis; Retinopathy; Fluoropyrimidine derivatives; Low molecular weight heparin; Intraoperative; Proliferative vitreoretinopathy; Vitreous body disease; Eye disease; Chemotherapy; Surgery; Double blind study; Pyrimidine derivatives; Vitrectomy; Fluorouracil
• ISSN: 0161-6420; 1549-4713
• DOI: 10.1016/S0161-6420(01)00589-9

To assess the safety and efficacy of adjuvant combination therapy using 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) for prevention of proliferative vitreoretinopathy (PVR) after vitrectomy and retinal reattachment surgery. Prospective randomized, double-masked, placebo controlled trial. One hundred seventy-four high-risk patients were randomized to receive either 5-FU and LMWH therapy or placebo. Patients were selected from all patients undergoing primary vitrectomy for rhegmatogenous retinal detachment. Results of standard surgery with 5-FU and LMWH therapy or placebo were compared at the 6-month follow-up. Development of postoperative PVR, retinal reattachment at 6 months after surgery, single operation reattachment rate, number of reoperations, and best-corrected visual acuity. There were 87 patients in the 5-FU and LMWH therapy group and 87 in the placebo group. The incidence of postoperative PVR was significantly lower ( P = 0.02) in the 5-FU and LMWH therapy compared with the placebo group. In 26.4% (23/87) of the placebo group and in 12.6% (11/87) of the 5-FU and LMWH group, postoperative PVR developed. In the 5-FU and LMWH group, the number of patients undergoing more than one operation was 19.5% (17/87) and the number of reoperations resulting from PVR was 52.9% (9/17). In the placebo group, the number of patients undergoing more than one operation was 25.3% (22/87) and the number of reoperations resulting from PVR was 72.7% (16/22). The difference in visual acuity was not statistically different in the two treatment groups, although those patients in whom postoperative PVR developed tended to have poorer vision ( P < 0.0001). There were no differences in complication rates between the two groups. There is a significant reduction in the incidence of postoperative PVR in patients receiving the 5-FU and LMWH therapy and in the reoperation rate resulting from PVR. This trial shows that incidence of PVR can be reduced with inexpensive and simple pharmacologic treatment with 5-FU and LMWH and should be used routinely in the treatment of patients at risk of developing PVR.